alexa Vascular Complications in Inflammatory Bowel Disease: An ObservationalStudy

ISSN: 2476-1958

Journal of Inflammatory Bowel Diseases & Disorders

  • Review Article   
  • J Inflam Bowel Dis & Disor 2016, Vol 1(2): 111
  • DOI: 10.4172/2476-1958.1000111

Vascular Complications in Inflammatory Bowel Disease: An ObservationalStudy

Sara Campos*, Francisco Portela and Carlos Sofia
Gastroenterology Departement, Coimbra University Hospital, Coimbra, Portugal
*Corresponding Author: Sara Campos, Gastroenterology Departement, Coimbra University Hospital, Coimbra, Avenida Forças Armadas 39-3 Dto1600, Portugal, Tel: 351962776108, Email: [email protected]

Received Date: Jul 28, 2016 / Accepted Date: Aug 10, 2016 / Published Date: Aug 16, 2016


Introduction: Increasing evidence has raised an alert about the potential risk of vascular complications in Inflammatory Bowel Disease (IBD). Estimating the magnitude of this risk is imperative to better address IBD patients. The aim of this study was to determine the venous (VTE) and Arterial Thromboembolic Events rates (ATE), as well as the Cardiovascular Events (CVE) and related mortality in IBD inpatients.
Methods: Retrospective study including all inpatients from a tertiary hospital with IBD from 1st August 2006 to 31st May 2013 with an episode of VTE/ATE/CVE. The population was characterized using the following variables: IBD (age of diagnosis, type, location/extension/behavior using Montreal classification, activity, medication), vascular complication (diagnosis age, type, location), classical VTE and ATE/CVE risk factors, pharmacological venous thromboembolism prophylaxis and outcome (recurrence, 30-day mortality).
Results: We recorded 774 admissions of IBD patients, 28 (3.6%) with thromboembolic episode: 57% male gender; average age 58 ± 17 years (13.8%

Keywords: Inflammatory bowel diseases; Venous thromboembolism; Arterial thromboembolism


Inflammatory Bowel Diseases (IBD), both Crohn’s Disease (CD) and Ulcerative Colitis (UC), are chronic gastrointestinal disorders with an unknown etiology. However, it is widely accepted that an uncontrolled inflammatory immune response in genetically predisposed individuals plays an important role in its pathogeny [1]. Systemic inflammation rises both risk of arterial (ATE) and venous thromboembolisms (VTE) and increasing evidence has raised an alert about the potential risk of vascular complications in IBD [2]. With a prevalence between 1.2 and 6.7% in clinical studies [2-5], VTE is a well-known and feared complication of IBD [2,6] associated to a nonnegligible risk of recurrence [7] and morbimortality. However, despite several population-based studies [8], the true magnitude of the risk still remains unclear, as a result of methodological differences and heterogeneity across studies. Additionally, the reason for this increased risk of VTE is not completely understood. Acquired risk factors appear to be relevant and many of the hemostatic alterations parallel inflammatory activity [2]. Deep venous thrombosis (DVT) and pulmonary embolism (PE), as well as unusual sites of VTE, such as cerebrovascular, portal and mesenteric veins, have been described.

Unlike VTE, the risk of ATE and cardiovascular events (CVE) in IBD is worse understood. Inflammation is involved throughout all stages of atherosclerosis pathogenesis, from plaque initiation to rupture and subsequent thrombosis [9]. C-reactive protein, often elevated during IBD flares, has also been associated with an increased risk of coronary artery disease independent of traditional cardiovascular risk factors [10]. Of note, other chronic inflammatory diseases, such as rheumatoid arthritis, are also associated with an increased of ATE and cardiovascular mortality [11,12].

Estimating the magnitude of the risk of VTE and ATE/CVE is imperative to better address IBD patients, namely regarding thromboembolic prophylaxis in patients who are already naturally predisposed to bleeding events, a subject that is still under investigation [13].

The aim of this study was to determine the VTE and ATE/CVE events and related mortality in inpatients with IBD.


Study design

- Type of study: observational retrospective study.

- Setting and location: Gastroenterology department of Centro Hospitalar e Universitário de Coimbra (CHUC), Portugal.

- Time frame: From 1st August 2006 to 31st May 2013. Study population:

- Inclusion criteria: all male and female patients, 18 years or older, with an established diagnosis of IBD and an admission between the time frame with an episode of VTE or ATE/CVE.

- Exclusion criteria: Patients with a VTE/ATE/CVE episode previous to the IBD diagnosis.


IBD diagnosis, both CD and UC, were based on clinical, endoscopic, histological and radiological criteria defined by European Crohn’s and Colitis Organization [14,15].

The diagnosis of VTE followed international guidelines, based on appropriate imaging techniques [16,17]. DVT of the lower or upper limbs was established by Doppler ultrasound and PE was diagnosed performing a Helical Computer Tomography (CT) of the chest or, in the presence of a contraindication for it, a Pulmonary Scintigraphy. Where PE had occurred with concomitant DVT, the thromboembolic event was counted as PE only. Thrombosis of portal, superior mesenteric, splenic or cerebral veins were diagnosed by abdominal and brain Contrast Enhanced CT, respectively.

Myocardial Infarction (MI) was diagnosed using electrocardiogram and/or markers of MI [18], while a Ischemic Stroke was diagnosed using Cranial CT scan or Magnetic Resonance Imaging (MRI) [19] and peripheral arterial ischemia using Doppler ultrasound and/or Angiography

Variables collected

The study population was characterized using the following variables, all determined by review of hospital records and IBD database:

IBD-related parameters – age at diagnosis; type (UC, CD); location, extension and behavior using Montreal classification [20]; activity at the time of the TE events described below; medication. As in other study [21], we used corticosteroid prescription, admission due to IBD and initiation of anti-TNFα treatment as surrogate measures for an active disease. In this sense, we defined: an active disease, if there was a flare (i.e. a 120 days period from the first steroid or anti-TNFα day prescription and/or admission for IBD, following 120 days free of corticosteroid or admissions due to IBD) or a persistent activity (i.e. those periods succeeding flare periods if additional hospitalizations, anti-TNFα treatment or steroid prescriptions had taken place within the 120 days from flare start); an inactive disease as any period starting 120 days after last hospitalization, anti-TNFα or corticosteroid prescription and ended at the time of reinitiating of corticosteroid treatment or hospitalization.

Vascular event-related – age of diagnosis, type (venous / arterial), location (venous – lower or upper limbs DVT, PE, portal, superior mesenteric, splenic or cerebral veins; arterial – MI, stroke, peripheral arterial ischemia).

Other potential confounding variables for VTE [22] – recent trauma or surgery (up to 3 months)[23], pregnancy, oral contraceptive use at the time of VTE, active cancer, laboratory thrombophilia workup if available, smoking status (unknown, active smoker, non-smoker), pharmacologic VTE prophylaxis

Other potential confounding variables for ATE/CVE [22] – smoking status, hypertension, diabetes mellitus, dyslipidemia.

Complications-related – recurrence, 30-day mortality.

Statistical analysis

Categorical variables were presented as absolute (n) and relative (%) frequencies and continuous variables through descriptive statistics, namely means and Standard Deviations (SD), or medians and interquartile ranges for variables with skewed distributions. The analysis was performed with SPSS 20.0 software.

Ethical aspects

The proposed study protocol meets the ethical investigational principles originated from the Declaration of Helsinki. Exceptionally, given the public health interest of this retrospective study and the observational design of the protocol, a consent form was not sent to the patients, whilst safeguarding: data collection from the physician subject to professional confidentiality and ethical code; the anonymity of the participants guaranteed by the assignment of an unique identification number that was only accessible to the investigators. All collected data was treated, published and presented in a grouped manner, in a way that participants’ identification was not possible.


Demographic and clinical data

The characteristics of IBD patients with a TE episode are described in Table 1: 57% male gender; average age 58 ± 17 years (13.8% <40 years); average IBD duration 13 ± 13 years; 57.1%-Ulcerative Colitis (E1-21%, E2-43%, E3-36%), 42.9%-Crohn's disease (L1-70%, L2-10%, L3-20%, B1-25%, B2-42%, B3-33%). Regarding IBD medication: 5- ASA (57%), thiopurines (23%), corticosteroids (15%), Anti-TNFα (12%).

Characteristic Descriptive data of IBD patients (n=28)
Gender – n (%)
Male 16 (57%)
Female 12 (42.9%)
Age (years) – mean ± SD 58 (17)
<40 years old – n (%) 4 (13.8%)
40-60 years old – n (%) 8 (27.6%)
>60 years old– n (%) 16 (58.6%)
Type of IBD – n (%)
UC 16 (57.1%)
DC 12 (42.9%)
Disease duration (years) – median (IQR) 11.5 (0-52)
IBD Montreal Classification – n (%)
Location and Extension E1 – 6 (21%), E2 – 12 (43%), E3 – 10 (36%)
  L1 – 20 (70%), L2 – 3 (10%), L3 – 5 (20%)
Behavior B1 – 7 (25)%, B2 – 12 (42%) , B3 – 9 (33%)
Active IBD – n (%) 12 (42.9%)
IBD therapeutics at TE event – n (%)
5-ASA 15 (57%)
Thiopurines 6 (23%)
Infliximab 3 (12%)
Corticosteroids 4 (15%)

Table 1: Descriptive analysis of IBD patients (Abbreviations: n=number; SD=standard deviation; IQR=interquartile range; CD=Crohn’s Disease; UC=Ulcerative Colitis; IBD=Inflammatory Bowel Disease; 5-ASA=5-aminosalicylic acid).

We recorded 774 admissions of patients with IBD, 28 (3.6%) with a TE episode.

Thromboembolic episode

The TE episodes are summarized in Figures 1 and 2. We registered 17 arterial (10 ischemic strokes, 6 MI, 1 peripheral arterial ischemia) and 11 venous (7 pulmonary thromboembolism - PTE, 3 deep vein thrombosis - DVT, 1 superior mesenteric vein thrombosis - SMVT) TE episodes.


Figure 1: Type of arterial thromboembolic complications(Ischemic stroke(blue)(N=10), Myocardial ischemia(Red)(N=6), Peripheral arterial ischemia(Green) (N=1)).


Figure 2: Type of venous thromboembolic complications (PTE(Blue)(N=7), DVT(Red)(N=3), SMVT(Green)(N=1)).


All patients with VTE [16,17] and ATE/CVE [2426]were treated following international guidelines.

We registered one recurrence: 40-year female patient with ulcerative proctitis and peripheral venous insufficiency with an episode of PE with extensive commitment of pulmonary tree. Thrombolysis was attempted, but it was complicated by a hypovolemic shock due to hemoperitoneum. Considering the risk versus benefit for surgical embolectomy, she was referred to an inferior vena cava (IVC) filter. She was later discharged under oral anticoagulation. During follow-up period, a Doppler ultrasound was requested due to the presence of varices in inferior limbs (internal safen vein territory) and large collateral circulation in the abdominal wall. A partial thrombosis in the IVC, probably in the area of the filter, plus a chronic thrombosis with partial recanalization of the left iliac vein axis and osteal and troncular left internal safen vein insufficiency were documented. As the varices were secondary, she didn’t fulfill the indication for surgery, and as the patient was a definitive IVC filter carrier, maintenance of anticoagulation plus conservative measures were adopted.

No deaths were registered

The characteristics of these two subgroups are detailed in Table 2.

Descriptive data of IBD patients
Characteristic Arterial TE (n=17) Venous TE (n=11)
Gender – n (%)
Male 10 (58.9%) 6 (54.5%)
Female 7 (41.1) 5 (45.5%)
Age (years) – mean ± SD 57 (17) 59 (17)
<40 years – n (%) 3 (17.6%) 2 (18.2%)
40-60 years – n (%) 4 (23.5%) 4 (36%)
>60 years – n (%) 10 (58.8%) 5 (54.5%)
Type of IBD – n (%)
UC 12 (70.6%) 5 (54.5%)
DC 5 (29.4%) 6 (45.5%)
IBD duration (years) – median (IQR) 12.5 (0-52) 11 (0-36)
Montreal Classification – n (%)
Location/Extension E1-5(30%), E2-9(50%), E3-3(20%) E1-1(10%), E2-2(20%), E3-8(70%)
  L1-10(60%), L2-3(15%), L3-4(25%) L1-6(54%), L2-3(23%), L3-3(23%)
Behavior B1-2(13%), B2-9(52%), B3-6(35%) B1-4(37%), B2-4(37%), B3-3(26%)
Active disease – n (%) 4 (23.5%) 8 (81%)
Active UC 2 3
Active CD 2 5
Current IBD therapy – n (%)
5-ASA 12 (73%) 4 (36%)
Thiopurines 10 (6%) 3 (27%)
Infliximab 2 (13%) 1 (9%)
Corticosteroids 3 (17.6%) 3 (27%)
Arterial Hypertension – n (%) 8 (47%) 0
Diabetes Mellitus – n (%) 3 (18%) 0
Dyslipidemia – n (%) 4 (23.5%) 0
Active smokers – n (%) 3 (17.6%) 2 (18.2%)
Surgery/Trauma – n (%) 0 5 (45.5%)
Pregnancy – n (%) 0 0
Active cancer – n (%) 0 0
Without VTE prophylaxis – n (%) 0 6 (54.5%)
Genetic hemostasis abnormalities
Factor V Leiden – n (%) 0 0
G20210A mutation – n (%) 0 0
MTHFR C677T – n (%) 1 heterozygote 0
Factor XIII val34leu –n (%) 0 1 homozygote
PAI-1 – n (%) 1 homo-/1 heterozygote 1 homo-/2 heterozygotes

Table 2: Descriptive analysis of IBD patients according to arterial/venous TE complication.


Our study showed that, in line with previous literature [27], TE is not uncommon in IBD inpatients, accounting for 3.6% of diagnosis. ATE events (2.2%) were slightly more frequent than VTE (1.4%) in our series.

Regarding IBD characteristics and arterial TE, MI and strokes were more common in UC patients than in CD, as previously observed [25,26]. As in general population, ATE events were more frequent in male gender and older ages, both well-known cardiovascular risk factors. Although Rungoe et al described higher cardiovascular risk in the first years after IBD diagnosis [27-29], we weren’t able to confirm it in our series, as the median IBD duration was 11.5 years. Nonetheless, this can be due to the fact that IBD diagnosis was made several years ago in a large percentage of cases and this was a retrospective study probably lacking some data, namely ATE events occurred at the onset of the disease. The fact that an active disease was not encountered in a major rate of cases (only in 17.6% of cases) could determine a minor role of the disease itself influencing the risk of ATE. IBD therapeutics may affect ATE risk [30]. An important percentage of patients were under steroids (20%), a drug known to increase the risk of TE [30]. It is also suggested [30] that 5-ASA and Anti-TNFα diminish this risk. We encountered a considerable rate of patients under these medications, but the percentage of patients under these medications and without an ATE event may be higher.

Concerning IBD characteristics and VTE, the role of IBD type in the risk of this complication is still controversial [27,31]. It is well known that the absolute risk of VTE increases with age, and that explains the mean age of the event in our series (mean age of 59 years). Papay et al didn’t find relevance in sex and disease duration [32], as we did. Although IBD location and extension aren’t consensual risk factors, some authors [33] defend that VTE is more frequent in more extensive disease, as we did. We found a high rate of ileal disease, but this is also the most frequent location of Crohn’s disease. A comparison with IBD without VTE should be made in other to confirm the role of these disease parameters in VTE. We didn’t find a predominant behavior of CD in VTE. Some studies [5] report a higher percentage of fistulising disease in VTE events, but, as mentioned before, we couldn’t do a direct comparison to evaluate this parameter. Amongst IBD therapeutics, mesalazine has been reported not to influence platelet aggregation or fibrinolytic activity [34]. Steroids increase platelet function and induce states of hypercoagulability and hypofibrinolysis, explaining the high percentage of steroids in VTE [35]. Contrarily, there is increasing evidence that Anti-TNFα reduces coagulation markers and activates fibrinolytic system [31], probably explaining the low percentage of Anti-TNFα users with VTE complication in our series.

Inflammation, probably through biological and biochemical effects exerted by the activation of the inflammatory pathways in the hemostatic system, takes an important role in ATE and VTE [2].

We found active IBD in 12 cases (42.9%; 4 ATE and 8 VTE).

Genetic abnormalities of hemostasis have been implicated in a low number of IBD patients with TE and are generally not found more often in IBD than in non-IBD conditions, suggesting that genetics may not explain a greater risk of VTE in IBD. In our sample, Factor V Leiden, the most prevalent thrombophilia reported in IBD [31], wasn’t encountered in any of our analyzed patients. Prothrombin G20210A mutation hasn’t been definitively associated with thrombosis in IBD [31] and wasn’t either found in any patient. MethyleneTetraHydroFolate Reductase (MTHFR) C677T mutation, increasing homocysteine plasma levels in homozygous carriers, hasn’t been significantly associated to a higher thrombotic risk in IBD [31] and it was found in 3 heterozygotes. Factor XIII val34leu mutation, increasing FXIII activation rate and reducing the risk TE in 20 to 40% of cases [31], has been encountered in similar prevalence in IBD patients and healthy controls and in thrombotic IBD patients and non- IBD thrombotic patients. We found a homozygote carrier of this mutation. PAI-1, a fibrinolysis inhibitor, homozygosity is associated with enhanced PAI-1 expression and contributes as an additional risk factor towards the development of VTE, but it doesn’t seem to differ between thrombotic IBD compared to non-IBD thrombotic patients [31]. We found 1 homozygote carrier.

Despite the publication of guidelines regarding TE prophylaxis in hospitalized IBD patients [13], more than 50% of patients weren’t under prophylaxis. Tinsley et al have previously also reported an elevated percentage of physicians not aware of any recommendations regarding this subject [36].

It is estimated that the recurrence of VTE is 2.5 times superior to general population risk and of 33% at 5 years [7], having active disease, male gender and age at the first VTE as risk factors. Unlike this data, we only reported 1 case of recurrent VTE, in a patient without active disease. It can be considered an iatrogenic complication of IVC filter. Complications of IVC filters are relatively common. One of the possible delayed complications is IVC thrombosis that can occur up to 22% of patients after 5 years and 33% after 9 years, independently of anticoagulation’s use and duration [37].

We didn’t report any death. IBD has been associated with elevated standardized mortality ratios, with VTE being one of the top 4 death causes [38]. Cardiovascular events haven’t been associated to higher mortality in IBD [27].

To the best of the authors’ knowledge, this study represents one of the largest case series of vascular complications in IBD inpatients, including venous and arterial events.

The retrospective design of the study, implying the lack of some records and shortage of data uniformisation, can be considered to be limitations of this study, as they didn’t allow us to create a control group and explore risk factors for TE in IBD. Hospitalization is also a risk factor to TE itself [39], and its role in TE etiology should be address independently. Other endpoints, as morbidity parameters, weren’t included in this study due to the same reason mentioned before. Nonetheless, it may be interesting to analyze it in future studies.


This study reinforces that TE events are not uncommon in IBD inpatients and there are several factors that may predispose to their development.

IBD activity seems to have a close relationship with VTE, in contrast to ATE, and other IBD characteristics (as disease type, location/ extension/behavior and therapeutics) may also influence that risk.

The concomitant presence of other risk factors demands (1) a better control of them in order to reduce the thromboembolic risk and (2) a development of other studies to determine the real role of IBD in TE’s etiology.

Additionally, a higher effort should be evoked to increase the rate of venous thromboembolic prophylaxis in hospitalized patients with IBD, as recommended by international guidelines.


Citation: Campos S, Portela F, Sofia C (2016) Vascular Complications in Inflammatory Bowel Disease: An Observational Study. J Inflam Bowel Dis & Disord 1: 111. Doi: 10.4172/2476-1958.1000111

Copyright: © 2016 Campos S et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment
Share This Article
Relevant Topics
Article Usage
  • Total views: 9195
  • [From(publication date): 12-2016 - Dec 18, 2017]
  • Breakdown by view type
  • HTML page views: 9120
  • PDF downloads: 75

Post your comment

captcha   Reload  Can't read the image? click here to refresh